Recommended dosing schedule of KISQALI.

KISQALI offers patients simple, once-daily dosing1

 

KISQALI in combination with an AI for premenopausal and postmenopausal women1

Table showing the recommended dosing schedule over a 28-day cycle with KISQALI + AI

  • Please refer to the summary of product characteristics for the recommended dose of the chosen AI.
  • In premenopausal women, an LHRH agonist should be administered according to current clinical practice guidelines when given with KISQALI.
  • Treatment of pre- and perimenopausal women with Kisqali plus AI should also include an LHRH agonist in accordance with local clinical practice.

 

KISQALI in combination with fulvestrant for postmenopausal women1

Table showing the recommended dosing schedule over a 28-day cycle with KISQALI + fulvestrant

 

  • When given with KISQALI, the recommended dose of fulvestrant is 500 mg, administered on Days 1, 15 and 29, and once monthly thereafter. Please refer to the summary of product characteristics for fulvestrant for additional details.

 

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

AI, aromatase inhibitor; LHRH, luteinising hormone-releasing hormone.

References

  1. KISQALI® (ribociclib) Summary of Product Characteristics.
  2. Fulvestrant Summary of Product Characteristics.
November 2021 | IE 172816-1

Click here for Product Information

Reporting of side effects
Adverse events (side effects) can be reported via the HPRA. Reporting forms and information can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling (01) 2080 612. For information on any of our medicinal products please contact Medical Information on (01) 260 1255.

×

Ask Speakers

×

Medical Information Request